HER2 antibody (V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian)) (C-Term)

Details for Product anti-ERBB2 Antibody No. ABIN180481, Supplier: Log in to see
Antigen
  • CD340
  • HER-2
  • HER-2/neu
  • HER2
  • MLN 19
  • NEU
  • NGL
  • TKR1
  • Erbb-2
  • Neu
  • c-erbB2
  • c-neu
  • mKIAA3023
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
  • v-erb-b2 avian erythroblastic leukemia viral oncogene 2
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
  • ERBB2
  • Erbb2
Alternatives
anti-Human HER2 antibody for Cell Culture
Epitope
C-Term
103
85
72
71
57
54
54
48
46
35
26
24
22
22
20
20
20
20
20
20
20
20
20
20
19
19
19
18
17
15
13
13
13
12
11
8
8
8
8
8
7
7
6
6
6
5
5
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
1374
497
330
36
34
15
13
8
6
5
4
3
3
3
2
1
1
1
1
1
Host
Rabbit
1000
518
30
16
12
5
1
Clonality (Clone)
Monoclonal ()
Conjugate
This HER2 antibody is un-conjugated
76
66
59
54
46
41
19
19
12
12
11
10
10
9
8
8
8
8
8
7
7
7
7
7
7
7
7
6
3
2
2
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
713
602
314
311
309
306
269
138
113
102
89
21
19
14
8
6
6
5
5
3
3
3
2
1
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen A synthetic cyclic peptide from the antigen's C-terminus.
Clone BV5
Isotype IgG
Specificity Cellular Localization:Membrane.
Characteristics Synonyms: HER-2, NEU, p185erbB2, NGL, c-erbB-2, MNL19, Receptor tyrosine-protein kinase erbB-2,NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2
Purification Supernatant
Alternative Name CD340 / ERBB2 / HER2 (ERBB2 Antibody Abstract)
Background HER2/neu (also known as c-erbB-2) is a member of the epidermal growth factor receptor (EGFR) family notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-bound tyrosine kinase normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is a proto-oncogene located at the long arm of human chromosome 17(17q11.2-q12).Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2
Gene ID 2064
UniProt P04626
Pathways RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development
Application Notes Positive Control: Breast carcinoma
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer Buffer pH 7.5, containing BSA as stabilizer and Sodium Azide as preservative.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store the antibody (undiluted) at 2-8 °C.
Shelf life: one year from despatch.
Expiry Date 12 months
Background publications Jacobs, Gown, Yaziji, Barnes, Schnitt: "HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement." in: American journal of clinical pathology, Vol. 113, Issue 2, pp. 251-8, 2000 (PubMed).

Gorlick, Huvos, Heller, Aledo, Beardsley, Healey, Meyers: "Expression of HER2/erbB-2 correlates with survival in osteosarcoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 17, Issue 9, pp. 2781-8, 2000 (PubMed).

Keshgegian, Cnaan: "erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody." in: American journal of clinical pathology, Vol. 108, Issue 4, pp. 456-63, 1997 (PubMed).

Wright, Nicholson, Angus, Sainsbury, Farndon, Cairns, Harris, Horne: "Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer." in: British journal of cancer, Vol. 65, Issue 1, pp. 118-21, 1992 (PubMed).

Wright, Angus, Nicholson, Sainsbury, Cairns, Gullick, Kelly, Harris, Horne: "Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer." in: Cancer research, Vol. 49, Issue 8, pp. 2087-90, 1989 (PubMed).